Malaria Vaccines For 2022

Authored by
Last reviewed
June 20, 2022

Malaria Vaccines 2022

According to the U.S. CDC, Malaria is a vaccine-preventable mosquito-borne disease caused by a parasite. On October 6, 2021, the World Health Organization (WHO) recommended the RTS,S malaria vaccine for sub-Saharan Africa and other regions with moderate to high malaria transmission.

And the Gavi Board recently approved support for malaria vaccines for eligible countries in sub-Saharan Africa for 2022-2025. An initial investment of US$ 155.7 million will empower this new malaria vaccine to "help drive down child mortality in Africa."

The WHO guidance is now available to countries as they consider whether and how to adapt the RTS,S malaria vaccine into their national malaria control strategies. The WHO recommendation for the vaccine was recently added to WHO’s consolidated malaria guidelines, and WHO has also published an updated position paper on the vaccine. On March 15, 2022, malaria vaccine experts – Dr. Mary Hamel, Dr. Richard Mihigo, and Dr. Akpaka Kalu – updated how the WHO supports malaria vaccinations.

According to Coherent Market Insights, the malaria vaccine market segment was valued at $41 million in 2022 and is expected to realize an annual growth rate of about 29% thru 2030.

As of June 20, 2022, the U.S. FDA had not approved a malaria vaccine.

Malaria Vaccines - Approved

Mosquirix RTS,S/AS01 Malaria Vaccine - GSK's Mosquirix RTS, S/AS01 is a recombinant vaccine consisting of the P. falciparum circumsporozoite protein from the pre-erythrocytic stage. Mosquirix aims to trigger the immune system to defend against the first stages when the Plasmodium falciparum malaria parasite enters the human host's bloodstream through a mosquito bite and infects liver cells.

Malaria Vaccine - Candidates

R21 / Matrix-M Malaria Vaccine - Serum Institute of India's R21 vaccine candidate is produced by expressing recombinant HBsAg virus-like particles in Hansenula polymorpha, comprising the central repeat and the C-terminus of the circumsporozoite protein fused to the N-terminal end of HBsAg10. 

RH5.1/AS01 Malaria Vaccine - RH5.1/AS01 is a novel recombinant malaria antigen developed at the University of Oxford.

mRNA Malaria Vaccine - BioNTech is building the first vaccine for malaria based on mRNA technology to eradicate mosquito-borne illness.

Malaria Vaccine Availability 2022

As of June 2022, malaria vaccinations were offered in Ghana, Kenya, and Malawi.

Malaria Vaccine News 2021 - 2022

June 10, 2022 - The journal Science Immunology published: Clonal evolution and TCR specificity of the human TFH cell response to Plasmodium falciparum CSP. Findings: These data suggest that the high parasite diversity in endemic areas will limit boosting of the vaccine-induced TFH cell response by natural infections. Our findings may guide the further design of PfCSP-based malaria vaccines able to induce potent T helper cell responses for broad, long-lasting antibody responses.

April 26, 2022 - The Government of India’s vaccination efforts has resulted in an 86.45% decline in Malaria cases and 79.16% reduction in Malaria related deaths in 2021 as compared to 2015.”

April 21, 2022 - The WHO announced more than 1 million children in Ghana, Kenya, and Malawi have received one or more doses of the RTS,S/AS01 (RTS,S) vaccine and that it substantially reduces deadly severe malaria.

April 13, 2022 - The media reported Ahmedabad Municipal Corporation in India had confirmed 36 malaria cases in 2022.

March 14, 2022 - Medicines for Malaria Venture announced that the Australian Therapeutic Goods Administration approved the use of single-dose Kozenis (tafenoquine) in children aged two years and above in combination with chloroquine for the radical cure (prevention of relapse) of Plasmodium vivax (P. vivax) malaria. The approval includes a novel, 50 mg dispersible tablet that can be dispersed in water.

March 4, 2022 - The WHO published an updated position paper on the RTS,S/AS01 (RTS,S) malaria vaccine that includes the October 2021 recommendation calling for the wider use of the vaccine among children living in areas of moderate-to-high P. falciparum malaria transmission. The paper complements the recent addition of the recommendation to the WHO Guidelines for malaria.

February 3, 2022 - The NEJM published an Original Article: Mosquito Net Use in Early Childhood and Survival to Adulthood in Tanzania. And a related Editorial offered further insights.

January 17, 2022 - The Lancet published a review that concluded by stating 'individualized conservative fluid management is recommended in patients with severe malaria.' This study focused on fluid therapy as an essential supportive measure for patients with severe malaria. Patients with severe malaria usually have an average cardiac index, vascular resistance, blood pressure, and a small degree of hypovolaemia due to dehydration. Cell hypoxia, reduced kidney function, and acidosis result from microcirculatory compromise and malarial anemia, which minimize tissue oxygenation, not hypovolaemia. Hence, aggressive fluid loading does not correct acid-base status, enhance kidney function, or improve patient outcomes, and it risks complications such as pulmonary edema.

December 6, 2021 - According to WHO's latest World malaria report, there were an estimated 241 million malaria cases and 627 000 malaria deaths worldwide in 2020. 

November 30, 2021 - BMC reported in a historically high transmission setting; a marked reduction followed the implementation of highly effective vector control interventions in antibiotic treatment of children. This added benefit of malaria control could have important implications for antibiotic prescribing practices, efforts to curtail antimicrobial resistance, and health system costs.

November 18, 2021 - The Lancet published a study: Assessment of experimental malaria vaccine-induced protection in pre-exposed populations. In the field of P falciparum malaria vaccine development, the availability of the controlled human malaria infection (CHMI) model has helped to systematically select vaccine candidates, including the advanced subunit vaccines RTS,S (now recommended by WHO), R21, and the whole, live organism-based vaccine, PfSPZ Vaccine, for further clinical development.

November 17, 2021 - A presentation was given at the 70th annual meeting of the American Society of Tropical Medicine and Hygiene. This study was conducted better to characterize COVID-19 in a high malaria transmission setting and to determine the burden/describe the clinical impact of SARS-CoV-2 and malaria co-infection. Conclusion: Though Covid-19 patients with P. falciparum infection had a higher frequency of confusion and vomiting, co-infection with malaria did not seem harmful. Low previous malaria exposure was associated with severe/critical Covid-19 and adverse outcomes.

October 29, 2021 - The World Health Organization endorsed the first-ever vaccine against malaria. This achievement is the product of 30 years of research and development.